U.S., June 16 -- ClinicalTrials.gov registry received information related to the study (NCT07646821) titled 'A Phase 1b/2 Study of Ropeginterferon Alfa-2b Added to Azacitidine in Newly Diagnosed MDS/AML (>= 10% Blasts) With TP53 Mutations' on June 09.
Brief Summary: To find the recommended dose of ropeginterferon alfa-2b in combination with azacitidine in patients with newly diagnosed MDS/AML with TP53 mutations. To learn if the recommended dose of ropeinterferon alfa-2b found in Dose Escalation in combination with azacitidine can help to control the disease.
Study Start Date: Nov. 27, 2026
Study Type: INTERVENTIONAL
Condition:
Ropeginterferon
Alfa-2b
Azacitidine
MDS/AML
Intervention:
DRUG: ropeginterferon alfa- 2b
Given by iv
DRUG...